FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial

Source: 
Endpoints
snippet: 

In a swift turnaround, Sarepta announced that it has cleared the FDA’s concerns about its gene therapy program for Duchenne muscular dystrophy, convincing regulators to lift a clinical hold issued just two months ago.